Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Tyrosine phosphorylation: thirty years and counting.

Hunter T.

Curr Opin Cell Biol. 2009 Apr;21(2):140-6. doi: 10.1016/j.ceb.2009.01.028. Epub 2009 Mar 9. Review.

2.

DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.

Abbassi R, Johns TG, Kassiou M, Munoz L.

Pharmacol Ther. 2015 Jul;151:87-98. doi: 10.1016/j.pharmthera.2015.03.004. Epub 2015 Mar 17. Review.

PMID:
25795597
3.
4.

Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis.

Cepero V, Sierra JR, Giordano S.

Curr Pharm Des. 2010;16(12):1396-409. Review.

PMID:
20166985
5.

The role of tyrosine phosphorylation in cell growth and disease.

Hunter T.

Harvey Lect. 1998-1999;94:81-119. Review. No abstract available.

PMID:
11070953
6.

Tyrosine kinase inhibitors in pediatric malignancies.

Skolnik JM, Adamson PC.

Cancer Invest. 2007;25(7):606-12. Review.

PMID:
17952738
7.

Tyrosine kinases as targets in cancer therapy - successes and failures.

Traxler P.

Expert Opin Ther Targets. 2003 Apr;7(2):215-34. Review.

PMID:
12667099
8.
9.

[Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].

Grimm CF, Blum HE, Geissler M.

Dtsch Med Wochenschr. 2005 May 27;130(21):1318-22. Review. German. No abstract available.

PMID:
15902620
10.

EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.

Quatrale AE, Porcelli L, Silvestris N, Colucci G, Angelo A, Azzariti A.

Front Biosci (Landmark Ed). 2011 Jan 1;16:1962-72. Review.

PMID:
21196276
11.

[Protein tyrosine kinase inhibitors in cancer therapy].

Boutayeb S, Zakkouri FZ, Aitelhaj M, Mesmoudi M, Boutayeb A, Boutayeb W, Mrabti H, Errihani H.

Pathol Biol (Paris). 2012 Aug;60(4):229-33. doi: 10.1016/j.patbio.2012.05.007. Epub 2012 Jun 26. Review. French.

PMID:
22743095
12.

The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer.

Haisa M.

J Int Med Res. 2013 Apr;41(2):253-64. doi: 10.1177/0300060513476585. Epub 2013 Mar 5. Review.

PMID:
23569026
13.

Tyrosine kinases as targets for cancer therapy.

Krause DS, Van Etten RA.

N Engl J Med. 2005 Jul 14;353(2):172-87. Review. No abstract available.

14.

Nuclear tyrosine phosphorylation: the beginning of a map.

Cans C, Mangano R, Barilá D, Neubauer G, Superti-Furga G.

Biochem Pharmacol. 2000 Oct 15;60(8):1203-15. Review.

PMID:
11007959
15.

[ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy].

Klener P, Klener P Jr.

Klin Onkol. 2010;23(4):203-9. Review. Czech.

PMID:
20806817
16.

Protein tyrosine phosphorylation and protein tyrosine nitration in redox signaling.

Monteiro HP, Arai RJ, Travassos LR.

Antioxid Redox Signal. 2008 May;10(5):843-89. doi: 10.1089/ars.2007.1853. Review.

PMID:
18220476
17.

Tyrosine kinase inhibitors in veterinary medicine.

London CA.

Top Companion Anim Med. 2009 Aug;24(3):106-12. doi: 10.1053/j.tcam.2009.02.002. Review.

PMID:
19732728
18.

Structural biology contributions to tyrosine kinase drug discovery.

Cowan-Jacob SW, Möbitz H, Fabbro D.

Curr Opin Cell Biol. 2009 Apr;21(2):280-7. doi: 10.1016/j.ceb.2009.01.012. Epub 2009 Feb 7. Review.

PMID:
19208462
19.

Inhibitors of signal transduction protein kinases as targets for cancer therapy.

Mikalsen T, Gerits N, Moens U.

Biotechnol Annu Rev. 2006;12:153-223. Review.

PMID:
17045195
20.

Another piece of the p27Kip1 puzzle.

Kaldis P.

Cell. 2007 Jan 26;128(2):241-4. Review.

Supplemental Content

Support Center